Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (1742)	5/24/2001 10:17:46 PM
From: Ian@SI	Respond to of 2344

Only a target of $18 US. Obviously, this company needs to spend more faster on R&D. ;^) Biomira Inc. BIOM Ladenburg Thalmann NT/LT Strong Buy $18

To: Ian@SI who wrote (1742)	5/25/2001 12:10:05 AM
From: Jibacoa	Read Replies (1) \| Respond to of 2344

Ian: I listened to the entire conference, but could not understand either what he meant with "I'm quite confident.".<g> I think I heard him to say that they have about 300 patients that have been in the program for almost 2 years. If that is the case, they may have enough data at the time for the "early look" to show some statistical significant difference, in order for them to apply for an NDA on an expedite basis. I guess time will tell.<g> As he said this is the most extensive immunotherapeutic trial for breast cancer that has been ever undertaken. And although anecdotal, Pat's results so far, taken into account that she had lung metastasis from her breast cancer, also seem quite encouraging since albeit the trial is "double-blind", you don't expect that kind of "placebo-effect".<g> RAGL Bernard